DOCS — Doximity, Inc.

Doximity Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $185 million, representing a 10% year-over-year growth and a 2% beat from the high end of guidance.
• Adjusted EBITDA: $111.4 million, with an adjusted EBITDA margin of 60%, exceeding prior guidance by 7%.
• Net Revenue Retention Rate: 112% on a trailing twelve-month basis, with top 20 customers at 117%.
• Free Cash Flow: $58.5 million generated in Q3.
• Share Repurchase: $196.8 million in shares repurchased during the quarter; $83 million remaining in the existing program, with a new $500 million repurchase authorization approved.

2. Strategic Updates and Business Highlights

• User Growth: Surpassed 3 million registered members, including over 85% of US physicians and two-thirds of NPs and PAs.
• AI Integration: Over 300,000 unique prescribers utilized Doximity's AI products in Q3, with high engagement rates.
• Telehealth Leadership: Doximity Dialer ranked as the top telehealth platform for the fifth consecutive year.
• AI Product Development: Focus on building trust in AI tools through a peer review system involving over 10,000 physician experts.

3. Forward Guidance and Outlook

• Q4 2026 Revenue Guidance: Expected in the range of $143 million to $144 million (4% growth at midpoint).
• Full Fiscal Year 2026 Revenue Guidance: Projected between $642.5 million and $643.5 million (13% growth at midpoint).
• Adjusted EBITDA for Full Year: Expected between $355.5 million and $356.5 million, maintaining a 55% adjusted EBITDA margin.
• Market Growth Assumption: Anticipated market growth of approximately 5% in calendar 2026, with expectations to exit the year with double-digit growth.

4. Bad News, Challenges, or Points of Concern

• Policy Headwinds: Uncertainty surrounding recent policy changes impacted client budgets, leading to delays in deal signings and lower upfront budget deployments.
• AI Infrastructure Costs: Increased investments in AI infrastructure are expected to pressure margins, with gross margin declining to 91% from 93% year-over-year.
• Competitive Pressures: The crowded AI market presents challenges, with Doximity needing to differentiate its offerings amidst rising competition.

5. Notable Q&A Insights

• Budget Dynamics: Clients expressed uncertainty regarding budget allocations due to recent policy changes, particularly related to most favored nation agreements affecting pharma spending.
• AI Monetization Strategy: Doximity plans to commercialize AI products later in the year, with no revenue currently included in guidance.
• Market Positioning: The company aims to leverage its established relationships and trust with physicians to capture a larger share of the AI market.
• Talent Acquisition: The competitive landscape for AI talent is intensifying, but Doximity's mission-driven culture is seen as a strength in retaining key personnel.

Overall, Doximity reported solid financial results and strategic advancements, particularly in AI and user engagement, but faces challenges from policy uncertainties and competitive pressures in the evolving healthcare landscape.